[1] LIBERTO J, CHEN S, SHIH I, et al.Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: a Comprehensive Review[J].Cancers, 2022, 14(12): 2885. [2] HAN B, ZHENG R, ZENG H, et al.Cancer Incidence and Mortality in China, 2022[J].Journal of the National Cancer Center, 2024, 4(1): 47-53. [3] WEBB P, JORDAN S.Global Epidemiology of Epithelial Ovarian Cancer[J].Nature Reviews Clinical Oncology, 2024, 21(5): 389-400. [4] ALI A, AL-ANI O, AL-ANI F.Epidemiology and Risk Factors for Ovarian Cancer[J].Przeglad Menopauzalny, 2023, 22(2): 93-104. [5] SACKS D, BAXTER B, CAMPBELL B, et al.Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke[J].International Journal of Stroke, 2018, 13(6): 612-632. [6] NUNES M, BARTOSCH C, ABREU M, et al.Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options[J].Cells, 2024, 13(9): 786. [7] LOH J, MA S.Hallmarks of Cancer Stemness[J].Cell Stem Cell, 2024, 31(5): 617-639. [8] PÉREZ-GONZÁLEZ A, BÉVANT K, BLANPAIN C. Cancer Cell Plasticity during Tumor Progression, Metastasis and Response to Therapy[J].Nature Cancer, 2023, 4(8): 1063-82. [9] CHIARA B, HILARY AK, MELISSA Z, et al.Tumor Microenviro-nment-Induced FOXM1 Regulates Ovarian Cancer Stemness[J].Cell Death & Disease, 2024, 15(5): 370. [10] HUANG Z, BYRD O, TAN S, et al.Periostin Facilitates Ovarian Cancer Recurrence by Enhancing Cancer Stemness[J].Scientific Reports, 2023, 13(1): 21382. [11] MOTOHARA T, KATABUCHI H.Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance[J].Cancers(Basel),2019, 11(7): 907. [12] DUAN XN, HU HL, WANG LZ, et al. Aldehyde Dehydrogenase 1 Family: a Potential Molecule Target for Diseases[J/OL].Cell Biology International,(2024-05-21)[2025-01-26].https://pubmed.ncbi.nlm.nih.gov/38800962/. [13] KAROLINA F, BARTŁOMIEJ B. The Role of Cancer Stem Cell Markers in Ovarian Cancer[J].Cancers(Basel),2024, 16(1): 40. [14] RUSCITO I, DARB-ESFAHANI S, KULBE H, et al.The Prognostic Impact of Cancer Stem-Like Cell Biomarker Aldehyde Dehydrogenase-1(ALDH1) in Ovarian Cancer: a Meta-Analysis[J].Gynecologic Oncology, 2018, 150(1): 151-157. [15] GUO Q, YANG CX, GAO F.The State of CD44 Activation in Cancer Progression and Therapeutic Targeting[J].Federation of European Biochemical Societies, 2021, 289(24): 16179. [16] CHUNG SY, HUNG YP, PAN YR, et al.Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway[J].Biomedicines, 2021, 9(8): 885. [17] MEIJUAN L, NA L, ZHAOXUE W, et al.Synthesis of a Celastrol Derivative as a Cancer Stem Cell Inhibitor through Regulation of the STAT3 Pathway for Treatment of Ovarian Cancer[J].RSC Medicinal Chemistry, 2024, 15(10): 3433-3443. [18] JIN Y, WANG C, ZHANG B, et al.Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer[J].International Journal of Biological Sciences, 2024, 20(4): 1314-1331. [19] JIANG YX, SIU MK, WANG JJ, et al.Ascites-Derived ALDH+CD44+Tumour Cell Subsets Endow Stemness, Metastasis and Metabolic Switch via PDK4-Mediated STAT3/AKT/NF-κB/IL-8 Signalling in Ovarian Cancer[J].British Journal of Cancer Research, 2020, 123(2): 275-287. [20] ZHANG TC, LIU Y, ZHANG MY.Research Progress on the Pharm-acology of Guizhi Fuling Wan[J].Journal of Liaoning University of Tradi-tional Chinese Medicine(辽宁中医药大学学报),2025, 27(2): 190-195. [21] LI SK. Mechanism of Guizhi Fuling Wan in Treating Uterine Fibroids[N].Popular Healthy News(大众健康报),2023-03-13(25). [22] YANG QJ,LU WZ, WANG LX.Clinical Efficacy of Guizhi Fuling Wan Combined with Modified Xiaoyaosan in the Treatment of Polycystic Ovary Syndrome and Its Influence on Sex Hormones and Recurrence Rate[J].The Journal of Medical Theory and Practice(医学理论与实践),2021, 34(24): 4313-4314. [23] JIANG SH, LI L, WU YS, et al.Mechanism of Guizhi Fuling Wan Inhibiting Proliferation of Human Breast Cancer Cells MCF-7[J].Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志),2018, 24(15): 132-136. [24] SONG TT, LIU GY, WANG YY, et al.The Sensitization Effect of Guizhi Poria Decoction on Postoperative Chemotherapy in Ovarian Cancer Patients and Its Impact on Inflammatory Factors and Immune Indices[J].Chinese Archives of Traditional Chinese Medicine(中华中医药学刊),2021, 39(5): 251-254. [25] ZHANG HY. Research Progress in Clinical Application of Guizhi Fuling Wan[J].Gansu Medical Journal(甘肃医药),2022, 41(2): 105- 106, 112. [26] TAO FF, SHEN MH, KONG LY, et al.An Analysis of Solar Term Medication Patterns in 778 Cases of Ovarian Cancer Prescriptions Using Data Mining Techniques[J].China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志),2016, 31(3): 1012-1016. [27] XUEZHEN W, PEIWEI S, QIAN H, et al.A Chinese Classical Prescription Guizhi-Fuling Wan in Treatment of Ovarian Cancer: an Overview[J].Biomed Pharmacother, 2022, 153: 113401. [28] LI ZT.The Efficacy of Guizhi Fuling Wan in Combination with Western Medicine for the Treatment of Advanced Ovarian Cancer[J].Clinical Research(临床研究),2020, 28(5): 130-132. [29] MA Q, CHEN F, LIU Y, et al.Integrated Transcriptomic and Proteomic Analysis Reveals Guizhi-Fuling Wan Inhibiting STAT3-EMT in Ovarian Cancer Progression[J].Biomed Pharmacother, 2024, 170: 116016. [30] WAN S, ZHAO E, KRYCZEK I, et al.Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells[J].Gastroenterology, 2014, 147(6): 1393-1404. [31] ZHAO DD, HOU LL, ZHANG JS, et al.Development of Three-Dimensional Cell Culture Technology and Its Applications to Stem Cells and Tumor Cells[J].Chinese Journal of Cell Biology(中国细胞生物学学报),2015, 37(8): 1140-1150. [32] LU T, BANKHEAD A, LJUNGMAN M, et al.Multi-Omics Profiling Reveals Key Signaling Pathways in Ovarian Cancer Controlled by STAT3[J].Theranostics, 2019, 9(19): 5478-5496. [33] JOHNSON DE, O'KEEFE RA, GRANDIS JR. Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer[J].Nature Reviews Clinical Oncology, 2018, 15(4): 234-248. [34] LOH JJ, MA S.Hallmarks of Cancer Stemness[J].Cell Stem Cell, 2024, 31(5): 617-639. [35] GOU R.Research and Progress in the Tumor Stem Cell Signaling Pathway(PI3K/AKT)[J].Harbin Medical Journal(哈尔滨医药),2021, 41(1): 139-141. [36] SILVA VR, SANTOS LS, DE CASTRO M, et al.A Novel Ruthenium Complex with 5-Fluorouracil Suppresses Colorectal Cancer Stem Cells by Inhibiting Akt/mTOR Signaling[J].Cell Death Discov ery, 2023, 9(1): 460. [37] HUANG BJ. Epstein-Barr Virus LMP1 Activates the PI3K/AKT/FOXO3a Pathway to Upregulate Human miR-21 and Promote Dryness and Drug Resistance in Nasopharyngeal Carcinoma Cells[EB/OL].(2017-02-28)[2025-01-26] .https://kns.cnki.net/kcms2/article/abstract?v=jNHD1hIvxn33KfJQX3s8a8S37OpUiLium_n2BKrND2p2-VZbmqG1AKCpt_2zIkMBh4IdPzaGkLhRvPbHnY-cL6By_r2qxpcmmyHodohyvkZR38jmQqxW3JDaK4nGo_yabzmtZc4LBeaHUNWGTAr5VIGZzlAiDv4PGo9I03LYUwY=&uniplatform=NZKPT. [38] YANG X, LIU Z, XU X, et al.Casticin Induces Apoptosis and Cytoprotective Autophagy while Inhibiting Stemness Involving Akt/mTOR and JAK2/STAT3 Pathways in Glioblastoma[J].Phytotherapy Research, 2024, 38(1): 305-320. [39] LI J, WANG ZH, DANG YM, et al.MTH1 Suppression Enhances the Stemness of MCF7 through Upregulation of STAT3[J].Free Radical Biology & Medicine, 2022, 188: 447-458. [40] CURYLOVA L, RAMOS H, SARAIVA L, et al.Noncanonical Roles of p53 in Cancer Stemness and Their Implications in Sarcomas[J].Cancer letters, 2022, 525: 131-145. [41] KARAMI FATH M, EBRAHIMI M, NOURBAKHSH E, et al.PI3K/Akt/mTOR Signaling Pathway in Cancer Stem Cells[J].Pathology, Research and Practice, 2022, 237: 154010. [42] SUN X, ZHANG Y, XIN S, et al.NOTCH3 Promotes Docetaxel Resistance of Prostate Cancer Cells through Regulating TUBB3 and MAPK Signaling Pathway[J].Cancer Science, 2024, 115(2): 412-426. [43] CUI CP, WONG CC, KAI AK, et al.SENP1 Promotes Hypoxia-Induced Cancer Stemness by HIF-1α deSUMOylation and SENP1/HIF-1α Positive Feedback Loop[J].Gut, 2017, 66(12): 2149-2159. [44] CHIPPALKATTI R, ABANKWA D.Promotion of Cancer Cell Stemness by Ras[J].Biochemical Society Transactions, 2021, 49(1): 467-476. [45] XU X, CHAI S, WANG P, et al.Aldehyde Dehydrogenases and Cancer Stem Cells[J].Cancer Letters, 2015, 369(1): 50-57. [46] WEI Y, LI Y, CHEN Y, et al.ALDH1: a Potential Therapeutic Target for Cancer Stem Cells in Solid Tumors[J].Frontiers in Oncology, 2022, 12: 1026278. [47] WEI CY, ZHU MX, YANG YW, et al.Downregulation of RNF128 Activates Wnt/β-Catenin Signaling to Induce Cellular EMT and Stemness via CD44 and CTTN Ubiquitination in Melanoma[J].Journal of Hematology&Oncology, 2019, 12(1): 21. [48] YU C, YUAN H, XU Y, et al.Hyaluronan Delays Human Amniotic Epithelial Stem Cell Senescence by Regulating CD44 Isoform Switch to Activate AKT/mTOR Signals[J].Biomed Pharmacother, 2024, 170: 116100. [49] ZHU SL, CHEN YH, YAO JP, et al.Cinnamaldehyde Regulates the CD44s/STAT3 Signaling Pathway to Inhibit Proliferation and Stemness of Pancreatic Cancer Cells[J].Chinese Pharmacological Bulletin(中国药理学通报),2022, 38(5): 676-683. [50] IZADPANAH A, MOHAMMADKHANI N, MASOUDNIA M, et al.Update on Immune-Based Therapy Strategies Targeting Cancer Stem Cells[J].Cancer Medicine, 2023, 12(18): 18960-18980. |